AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 142 min read$ONCY

Oncolytics Updates GOBLET Study Data Timelines, Expects Final PanCAN Grant Payment

Oncolytics Biotech (ONCY) updated its GOBLET study timelines, expecting final PanCAN grant payment in Q4 2026. Cohort 4 data is due in Q4 2026, with Cohort 5 results in H1 2027. Median overall survival in Cohort 4 exceeded expectations, and the company is winding down study infrastructure while monitoring remaining patients. ONCY is developing pelareorep for gastrointestinal cancers and is currently trading at $0.55, up 13.72%.

Original reporting
rttnews.com
Published Oct 14, 2026, 4:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 4:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Oncolytics Updates GOBLET Study Data Timelines, Expects Final PanCAN Grant Payment — source image
Source · rttnews.com
Decision brief

The 30-second read

$ONCYNeutralLow
01

Why it matters

The announced timelines set expectations for future data releases and a grant payment, which may modestly support the stock but lack immediate catalyst strength.

02

Market read

The article provides a first‑report update on study timelines and grant payment, offering limited but fresh information for traders monitoring ONCY.

03

What to watch

The final PanCAN grant payment could improve cash runway, reducing financing risk.

Relevance 7/10Novelty 6/10Timing: Q4 2026 grant payment and data readouts in 2026‑2027

Background

Oncolytics Biotech (ONCY) is a clinical‑stage company developing the oncolytic virus pelareorep. The GOBLET study evaluates pelareorep in combination with checkpoint inhibitors across gastrointestinal cancers.

Company-level read

Ticker impact

$ONCYNeutralMedium confidence
Context

Oncolytics Biotech announced updated timelines for its GOBLET Phase 1/2 study and expects a final PanCAN grant payment in Q4 2026.

Expected impact

potential modest upside as market anticipates positive cohort data later in 2026/2027

Evidence & confidence

No new efficacy results were disclosed, only future data release dates and a grant payment, limiting immediate price impact.

Market effects

Sector

Provides a modest catalyst for the oncolytic virotherapy sector but no broad sector shift.

Regional

Limited to U.S. biotech investors; no regional market effect.

Global

Low global relevance; primarily affects Oncolytics shareholders.

Counterpoint

What could challenge this read

Without concrete efficacy data, the timeline update may be a stalling tactic, suggesting caution.

Key entities

  • company
    Oncolytics Biotech Inc.

    Developer of pelareorep, subject of the article.

  • organization
    Pancreatic Cancer Action Network (PanCAN)

    Grantor of funding to Oncolytics for the GOBLET study.

Read at source← All news

StoryOncolytics completes GOBLET enrollment and schedules upcoming data readouts

Related articles

OCT 14
$ONCYLow

Oncolytics reports GOBLET study enrollment complete

Oncolytics Biotech (NASDAQ:ONCY) completed enrollment in its GOBLET Phase 1/2 study and expects final grant payment this quarter. Cohort 4 results are due in Q4 2026, with Cohort 5 results in H1 2027. The study, conducted in Germany, focuses on pelareorep-based therapies for cancer. The company plans to use data to guide future strategies. Pelareorep has Fast Track designation for colorectal, anal, and pancreatic cancer.

investing.com1 min
OCT 14
$ONCYMed

Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda

Global cancer drug spending reached $252B in 2024 and is forecast to exceed $400B by 2028, with the U.S. accounting for 46%. Several companies, including Oncolytics Biotech (ONCY), Revolution Medicines (RVMD), Eli Lilly (LLY), Genmab (GMAB), and Exelixis (EXEL), are advancing treatments for colorectal and pancreatic cancers. Oncolytics reported accelerating enrollment in a colorectal cancer study, while Revolution Medicines received FDA approval for a pancreatic cancer drug.

prnewswire.com3 min
SEP 30
$ONCYMedAI 8/10

Oncolytics Highlights Pelareorep Preclinical Findings In Hepatocellular Carcinoma

Oncolytics Biotech (ONCY) reported preclinical findings in PNAS showing pelareorep treatment may alter the tumor microenvironment in liver cancer, increasing PD-L1 and ICOSL levels, and CD8+ T-cell density. The company noted liver cancer is not a target indication but is studying pelareorep in colorectal cancer with an interim update expected by year-end 2026. ONCY stock closed at $0.67, down 2.05% in premarket.

rttnews.com2 min
SEP 29
$ONCYMedAI 8/10

Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy

ONCOLYTICS BIOTECH INC (ONCY) filed an SEC Form 8-K — Other Events. Oncolytics Biotech ® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy Data support pelareorep’s potential as a backbone therapy to transform immunologically inactive liver tumors into a phenotype

SEC EDGAR 8-K2 min
SEP 29
$ONCYMedAI 8/10

Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy

Oncolytics Biotech (Nasdaq: ONCY) announced data published in the Proceedings of the National Academy of Sciences showing pelareorep can alter the tumor microenvironment in liver cancer, making it susceptible to immunotherapy. The study demonstrated increased PD-L1 expression, ICOSL levels, and CD8+ T cell density. Oncolytics is developing pelareorep for metastatic gastrointestinal cancers and is pursuing strategic partnerships.

globenewswire.com2 min